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BINARY PROBE SYSTEM FOR SENSITIVE 
DETECTION OF TARGET ANALYTES 
CROSS REFERENCE TO RELATED 
APPLICATION 
This application claims priority to and benefit ofU.S. Pro-
visional Patent Application Ser. No. 61/328,791, filed on Apr. 
28, 2010, which is incorporated herein by reference in its 
entirety. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH OR DEVELOPMENT 
This disclosure was made with government support under 
NIH Grant No. R21 HG004060awarded by the U.S. National 
Institutes of Health of the United States government. The 
government has certain rights in the disclosure. 
TECHNICAL FIELD 
The present disclosure is generally related to systems for 
the detection of specific analytes using a binary probe and a 
reporter oligonucleotide. 
BACKGROUND 
Real time assays for the detection of specific nucleic acids 
are of great importance, since they enable instant detection of 
specific RNA/DNA sequences without the need of separating 
the probe-analyte hybrid from the unbound probe. Molecular 
beacon probes are a novel tool for real-time nucleic acid 
analysis (Tyagi & Kramer (1996) Nat. Biotechnol. 14: 303-
308; Marras et al., (2006) Clin. Chim. Acta. 363: 48-60; 
Wang, eta!., (2009)Angew. Chem. Int. Ed. Engl. 48: 856-870; 
Li et al., (2008) Biochem. Biophys. Res. Commun. 373: 457-
461; Venkatesan et al., (2008) Chem. Soc. Rev. 37: 648-663). 
The traditional molecular beacon is a stem-loop folded 
oligonucleotide with a fluorophore at the 5'-end and a 
quencher at its 3'-end. Hybridization to a complementary 
single-stranded DNA or RNA converts the molecular beacon 
into the elongated conformation, in which the fluorophore is 
remote from the quencher, resulting in high fluorescence. The 
simplicity and elegance of molecular beacon design has made 
this probe a popular tool for nucleic acid analysis and has 
served as an inspiration for a number of related assays (see, 
for example, Du et al., (2003) J. Am. Chem. Soc. 125: 4012-
4013; Ye et al., (2004)J.Am. Chem. Soc. 126: 7740-7741; Liu 
& Lu (2006)Methods Mal. Biol. 335: 275-288; Grossmann et 
al., (2007)Angew. Chem. Int. Ed. Engl. 46: 5223-5225; Linet 
al., (2008) Nucleic Acids Res. 36: e123). 
Molecular beacon probes are extensively used in real-time 
PCR assays (Whitman & Dunbar (2008) Recent Pat. DNA 
Gene Seq. 2: 20-26) and for RNA monitoring in living cells 
(Bao et al., (2009) Ann. Rev. Biomed. Eng. 11: 25-47; Tyagi. 
S. (2009) Nat. Methods 6: 331-338). Importantly, the stem-
loop structure not only brings the fluorophore close to the 
quencher but also improves the probe specificity. Molecular 
beacon probes discriminate between two nucleic acid 
sequences that differ by a single nucleotide in a wider tem-
perature range than do linear hybridization probes (Bonnet et 
al., (l999)Proc. Natl. Acad. Sci. USA. 96: 6171-6176). These 
properties are of particular importance for single nucleotide 
polymorphism (SNP) genotyping. 
One factor that limits the application of molecular beacon 
probes in SNP genotyping is their high synthetic cost. Chemi-
cal synthesis of a regular molecular beacon probe requires 
2 
conjugation of an oligonucleotide with two organic dyes, a 
fluorophore and a quencher. Moreover, at least one round of 
HPLC purification is required to remove fluorescent impuri-
ties, which cause high background fluorescence and reduce 
5 both the sensitivity and the dynamic range of the probe. 
Taking into account that the analysis of each individual SNP 
requires two molecular beacon probes (each complementary 
to a specific allele), genotyping thousands of SNPs by 
molecular beacon probes becomes expensive. Accordingly, a 
10 binary approach for nucleic acid recognition (Kolpashchikov 
D. M. (2005) J. Am. Chem. Soc. 127: 12442-12443; Kolpa-
shchikovD. M. (2006)J.Am. Chem. Soc., 128: 10625-10628; 
Kolpashchikov D. M. (2007) Chembiochem. 8: 2039-2042; 
Kolpashchikov D. M. (2008). J. Am. Chem. Soc. 130: 2934-
15 2935; Gerasimova et al., (2010) Chembiochem 11: 811-817) 
has been developed. In this approach two oligonucleotide 
probes form short hybrids with the analyte and generate a 
fluorescent signal upon tertiary complex formation. The 
approach enables SNP genotyping at room temperature with 
20 exceptional specificity. 
SUMMARY 
Briefly described, embodiments of this disclosure, among 
25 others, encompass systems, and their methods of use, for 
detecting a target analyte, wherein the system comprises: (a) 
a first oligonucleotide probe comprising: (i) atthe 5'-terminus 
thereof, a reporter oligonucleotide-binding arm having a 
nucleotide sequence complementary to the nucleotide 
30 sequence of a first region of a reporter oligonucleotide; and 
(ii) at the 3'-terminus thereof, an analyte-binding arm having 
a nucleotide sequence characterized as selectively binding to 
a first region of a target analyte; (b) a second oligonucleotide 
probe comprising: (i) at the 3'-terminus thereof, a reporter 
35 oligonucleotide-binding arm having a nucleotide sequence 
complementary to the nucleotide sequence of a second region 
of a reporter oligonucleotide; and (ii) at the 5'-terminus 
thereof, an analyte-binding arm having a nucleotide sequence 
characterized as selectively binding to a second region of a 
40 target analyte; ( c) a reporter oligonucleotide comprising: (i) a 
first region having a nucleotide sequence complementary to 
the reporter oligonucleotide-binding arm of the first oligo-
nucleotide probe; (ii) a second region having a nucleotide 
sequence complementary to the reporter oligonucleotide-
45 binding arm of the second oligonucleotide probe; (iii) a fluo-
rophore and a quencher disposed on the reporter oligonucle-
otide whereby the fluorophore and quencher interact in the 
absence of a target analyte to quench fluorescence generated 
by the fluorophore; and (iv) a cleavable site disposed between 
50 the fluorescent label and the quencher, wherein the cleavable 
site is characterized as cleavable by a protein enzyme or a 
region of the first or the second oligonucleotide probe; and ( d) 
an oligonucleotide-cleaving agent characterized as specifi-
cally cleaving the cleavable site of the reporter oligonucle-
55 otide. 
In embodiments ofthis aspect of the system of the disclo-
sure, the oligonucleotide-cleaving agent can be selected from 
the group consisting of an enzyme, a ribozyme, and a deox-
yribozyme, and the ribozyme, and a deoxyribozyme can be 
60 optionally derived from a configuration of a region of the first 
oligonucleotide probe, the second oligonucleotide probe, or 
both the first and the second oligonucleotide probe. 
In embodiments ofthis aspect of the system of the disclo-
sure, the oligonucleotide-cleaving agent can be an enzyme 
65 selected from the group consisting of: a restriction endonu-
clease, an RNase H, a Flap-endonuclease-1 (FEN-1), and a 
DNA glycosylase. In embodiments of this aspect of the sys-
US 8,859,266 B2 
3 
tern of the disclosure, the reporter oligonucleotide-binding 
arm of at least one oligonucleotide probe can comprise a 
nucleotide sequence configured as a deoxyribozyme oligo-
nucleotide-cleaving agent capable of specifically cleaving a 
site in the reporter oligonucleotide when the oligonucleotide 
probe is hybridized to the reporter oligonucleotide and to a 
target analyte. 
At least one of the first oligonucleotide probe and the 
second oligonucleotide probe can further comprise a linker 
connecting the analyte-binding arm and the reporter oligo-
nucleotide-binding arm of said oligonucleotide probe. 
The reporter oligonucleotide can be a molecular beacon 
characterized as having a stem-loop configuration in the 
absence of a target analyte. In embodiments of this aspect of 
the system of the disclosure, at least one of the fluorophore 
and the quencher can be attached to the reporter oligonucle-
otide at the 5' or the 3' terminus thereof. 
In embodiments ofthis aspect of the system of the disclo-
sure, the system can further comprise a target analyte that 
with the first and second oligonucleotide probes, and the 
reporter oligonucleotide forms a quadripartite complex. 
In embodiments ofthis aspect of the system of the disclo-
sure, the nucleotide sequences of the analyte-binding arms of 
the first and the second oligonucleotide probes can be inde-
pendently selected to specifically bind to a target analyte 
comprising a deoxyribonucleotide sequence, a ribonucle-
otide sequence, a double-stranded nucleic acid, a peptide, a 
polypeptide, or a variant thereof. 
The system of the disclosure, the system can further com-
prise a plurality of oligonucleotide probe pairs, each probe 
pair comprising a first oligonucleotide probe and a second 
oligonucleotide probe. The plurality of oligonucleotide probe 
pairs can selectively bind to a plurality of sites of a single 
target analyte or to a plurality of target analytes. 
In embodiments ofthis aspect of the system of the disclo-
sure, the first or the second oligonucleotide probe can be 
tethered to a substrate and can be disposed on the substrate as 
an array. 
Another aspect of the disclosure encompasses embodi-
ments of method of identifying a target nucleotide sequence 
comprising the steps of: (i) obtaining a test sample; (ii) form-
ing a reaction mix by combining the test sample with: (a) a 
first oligonucleotide probe comprising: (i) at the 5'-terminus 
thereof, a reporter oligonucleotide-binding arm having a 
nucleotide sequence complementary to the nucleotide 
sequence of a first region of a reporter oligonucleotide; and 
(ii) at the 3'-terminus thereof, an analyte-binding arm having 
a nucleotide sequence characterized as selectively binding to 
a first region of a target analyte; (b) a second oligonucleotide 
probe comprising: (i) at the 3'-terminus thereof, a reporter 
oligonucleotide-binding arm having a nucleotide sequence 
complementary to the nucleotide sequence of a second region 
of a reporter oligonucleotide; and (ii) at the 5'-terminus 
thereof, an analyte-binding arm having a nucleotide sequence 
characterized as selectively binding to a second region of a 
target analyte; ( c) a reporter oligonucleotide comprising: (i) a 
first region having a nucleotide sequence complementary to 
the reporter oligonucleotide-binding arm of the first oligo-
nucleotide probe; (ii) a second region having a nucleotide 
sequence complementary to the reporter oligonucleotide-
binding arm of the second oligonucleotide probe; (iii) a fluo-
rophore and a quencher disposed on the reporter oligonucle-
otide whereby said fluorophore and quencher interact in the 
absence of a target analyte to quench fluorescence generated 
4 
region of the first or the secondoligonucleotide probe, and ( d) 
an oligonucleotide-cleaving agent characterized as specifi-
cally cleaving the cleavable site of the reporter oligonucle-
otide; under conditions suitable for the formation of a quad-
ripartite complex between the analyte-binding arms of the 
first and the second oligonucleotide probes, a target analyte in 
the test sample, and the reporter oligonucleotide, thereby 
exposing a cleavable site of the reporter oligonucleotide for 
cleavage; (iii) allowing cleavage of a cleavable site of the 
10 
reporter oligonucleotide, thereby releasing the fluorophore, 
the quencher, or both the fluorophore and the quencher, from 
the complex; (iv) illuminating the reaction mix at a wave-
length suitable for inducing a fluorescent emission by the 
15 fluorophore; and ( v) detecting the fluorescence emitted by the 
fluorophore, thereby detecting the presence of the target ana-
lyte in the sample. 
Yet another aspect of the disclosure encompasses embodi-
ments of a kit comprising: (a) a first oligonucleotide probe 
20 comprising: (i) at the 5'-terminus thereof, a reporter oligo-
nucleotide-binding arm having a nucleotide sequence 
complementary to the nucleotide sequence of a first region of 
a reporter oligonucleotide; (ii) at the 3'-terminus thereof, an 
analyte-binding arm having a nucleotide sequence character-
25 ized as selectively binding to a first region of a target analyte; 
and (iii) optionally, a linker region covalently linking the 
reporter oligonucleotide-binding arm and the analyte-bind-
ing arm; (b) a second oligonucleotide probe comprising: (i) at 
the 3'-terminus thereof, a reporter oligonucleotide-binding 
30 arm having a nucleotide sequence complementary to the 
nucleotide sequence of a second region of a reporter oligo-
nucleotide; (ii) at the 5'-terminus thereof, an analyte-binding 
arm having a nucleotide sequence characterized as selectively 
binding to a second region ofa target analyte; and (iii) option-
35 ally, a linker region covalently linking the reporter oligo-
nucleotide-binding arm and the analyte-binding arm; (c) a 
reporter oligonucleotide comprising: (i) a first region having 
a nucleotide sequence complementary to the reporter oligo-
nucleotide-binding arm of the first oligonucleotide probe; (ii) 
40 a second region having a nucleotide sequence complemen-
tary to the reporteroligonucleotide-binding arm of the second 
oligonucleotide probe; (iii) a fluorophore and a quencher 
disposed on the reporter oligonucleotide whereby said fluo-
rophore and quencher interact in the absence of a target ana-
45 lyte to quench fluorescence generated by the fluorophore; and 
(iv) a cleavable site disposed between the fluorescent label 
and the quencher, wherein the cleavable site is characterized 
as cleavable by a protein enzyme or a region of the first or the 
second oligonucleotide probe; or a plurality of oligonucle-
50 otide probe pairs, each probe pair comprising a first oligo-
nucleotide probe and a second oligonucleotide probe, 
wherein the plurality of oligonucleotide probe pairs selec-
tively binds to a plurality of sites of a single target analyte or 
to a plurality of target analytes, and wherein one oligonucle-
55 otide probe in each probe pair optionally is tethered to a 
substrate, and optionally disposed on the substrate as an 
array; ( d) optionally, an oligonucleotide-cleaving agent char-
acterized as specifically cleaving the cleavable site of the 
reporter oligonucleotide; and ( e) packaging and instructions 
60 for the use of the kit to detect a target analyte in a test sample. 
BRIEF DESCRIPTION OF THE DRAWINGS 
by the fluorophore; and (iv) a cleavable site disposed between 65 
the fluorescent label and the quencher, wherein the cleavable 
site is characterized as cleavable by a protein enzyme or a 
Further aspects of the present disclosure will be more 
readily appreciated upon review of the detailed description of 
its various embodiments, described below, when taken in 
conjunction with the accompanying drawings. 
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FIG. 1 is a scheme illustrating an embodiment of Enz-
BDPl. 
FIG. 2 is a graph showing the fluorescence enhancement of 
Enz-BDPl together with RNase HII in the presence C•) or in 
the absence (0) of the analyte HepC30 (SEQ ID NO.: 1). 
FIG. 3 is a scheme illustrating an embodiment of Enz-
BDP2. 
FIG. 4 is a graph showing the fluorescence enhancement of 
Enz-BDP2 in the presence of the analyte HepC40 (SEQ ID 
NO.: 5) with C•) or without (0) RNase HII. 
FIG. 5 is a graph showing the fluorescence enhancement of 
Enz-BDP2 in the presence of the analyte HepC40 (SEQ ID 
NO.: 5) as a function of the analyte concentration. 
FIG. 6 is a scheme showing an RNase HU-based probe 
assay. A ribonucleotide inserted in the reporter oligonucle-
otide is indicated as rA. 
FIG. 7 is a scheme showing an endonuclease-based assay. 
FIG. 8 is a scheme showing a flap structure-forming probe. 
FIG. 9 is a scheme showing a glycosylase-based probe 
assay. The damaged or mismatch-forming fluorophore-la-
beled nucleotide is indicated as VF. 
FIG. 10 is a scheme showing microarrays of enzyme 
assisted pro bes. 
FIG. 11 is a scheme showing a deoxyribozyme-assisted 
binary probe. One (strand~) or both reporteroligonucleotide-
binding arms of the probe contain a deoxyribozyme 
sequence. The deoxyribozyme cleaves the reporter oligo-
nucleotide substrate in the quadripartite complex (Panel B). X 
in the reporter oligonucleotide indicates the cleavage site. 
FIG. 12 illustrates the quadripartite complex formed by the 
binding of the Enz-MB2 strands a and~ (SEQ ID NOs.: 6 and 
6 
embodiments only, and is not intended to be limiting, since 
the scope of the present disclosure will be limited only by the 
appended claims. 
Where a range of values is provided, it is understood that 
each intervening value, to the tenth of the unit of the lower 
limit unless the context clearly dictates otherwise, between 
the upper and lower limit of that range and any other stated or 
intervening value in that stated range, is encompassed within 
the disclosure. The upper and lower limits of these smaller 
10 ranges may independently be included in the smaller ranges 
and are also encompassed within the disclosure, subject to 
any specifically excluded limit in the stated range. Where the 
stated range includes one or both of the limits, ranges exclud-
ing either or both of those included limits are also included in 
15 the disclosure. 
Unless defined otherwise, all technical and scientific terms 
used herein have the same meaning as commonly understood 
by one of ordinary skill in the art to which this disclosure 
belongs. Although any methods and materials similar or 
20 equivalent to those described herein can also be used in the 
practice or testing of the present disclosure, the preferred 
methods and materials are now described. 
All publications and patents cited in this specification are 
herein incorporated by reference as if each individual publi-
25 cation or patent were specifically and individually indicated 
to be incorporated by reference and are incorporated herein 
by reference to disclose and describe the methods and/or 
materials in connection with which the publications are cited. 
The citation of any publication is for its disclosure prior to the 
30 filing date and should not be construed as an admission that 
the present disclosure is not entitled to antedate such publi-
cation by virtue of prior disclosure. Further, the dates of 
publication provided could be different from the actual pub-7, respectively; strand a italicized) to a target analyte (SEQ ID 
NO.: 5) of the HepC40 virus and to a reporter oligonucleotide 35 (SEQ ID NO.: 8). Small case letters indicate ribonucleotides 
lication dates that may need to be independently confirmed. 
As will be apparent to those of skill in the art upon reading 
this disclosure, each of the individual embodiments described 
and illustrated herein has discrete components and features 
which may be readily separated from or combined with the 
features of any of the other several embodiments without 
in the reporter oligonucleotide (MB2). 
FIG. 13 illustrates the quadripartite complex formed by the 
binding of a and ~ strand oligonucleotide probes (SEQ ID 
NOS.: 10 and 11, respectively) to a target analyte (SEQ ID 
NO.: 9) of the HepC virus and to a reporter oligonucleotide 
(SEQ ID NO.: 12). Each of the a and the~ strands includes a 
region, the sequence of which forms a deoxyribozyme. In this 
embodiment of a quadripartite complex, each of the strands 
encodes a different deoxyribozyme and each is located oppo-
site a cleavable ribonucleotide of the reporter oligonucle-
otide. Small case letters indicate ribonucleotides in the 
reporter oligonucleotide. 
The drawings are described in greater detail in the descrip-
tion and examples below. 
The details of some exemplary embodiments of the meth-
ods and systems of the present disclosure are set forth in the 
description below. Other features, objects, and advantages of 
the disclosure will be apparent to one of skill in the art upon 
examination of the following description, drawings, 
examples and claims. It is intended that all such additional 
systems, methods, features, and advantages be included 
within this description, be within the scope of the present 
disclosure, and be protected by the accompanying claims. 
DETAILED DESCRIPTION 
Before the present disclosure is described in greater detail, 
it is to be understood that this disclosure is not limited to 
particular embodiments described, and as such may, of 
course, vary. It is also to be understood that the terminology 
used herein is for the purpose of describing particular 
40 departing from the scope or spirit of the present disclosure. 
Any recited method can be carried out in the order of events 
recited or in any other order that is logically possible. 
Embodiments of the present disclosure will employ, unless 
otherwise indicated, techniques of medicine, organic chem-
45 istry, biochemistry, molecular biology, pharmacology, and 
the like, which are within the skill of the art. Such techniques 
are explained fully in the literature. 
It must be noted that, as used in the specification and the 
appended claims, the singular forms "a," "an," and "the" 
50 include plural referents unless the context clearly dictates 
otherwise. Thus, for example, reference to "a support" 
includes a plurality of supports. In this specification and in the 
claims that follow, reference will be made to a number of 
terms that shall be defined to have the following meanings 
55 unless a contrary intention is apparent. 
As used herein, the following terms have the meanings 
ascribed to them unless specified otherwise. In this disclo-
sure, "comprises," "comprising," "containing" and "having" 
and the like can have the meaning ascribed to them in U.S. 
60 patent law and can mean "includes," "including," and the like; 
"consisting essentially of' or "consists essentially" or the 
like, when applied to methods and compositions encom-
passed by the present disclosure refers to compositions like 
those disclosed herein, but which may contain additional 
65 structural groups, composition components or method steps 
(or analogs or derivatives thereof as discussed above). Such 
additional structural groups, composition components or 
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method steps, etc., however, do not materially affect the basic 
and novel characteristic( s) of the compositions or methods, 
compared to those of the corresponding compositions or 
methods disclosed herein. "Consisting essentially of' or 
"consists essentially" or the like, when applied to methods 
and compositions encompassed by the present disclosure 
have the meaning ascribed in U.S. patent law and the term is 
open-ended, allowing for the presence of more than that 
which is recited so long as basic or novel characteristics of 
that which is recited is not changed by the presence of more 10 
than that which is recited, but excludes prior art embodi-
ments. 
5-iodouracil, 5-ethyluracil, 5-propyluracil, 5-methoxyuracil, 
5-hydroxymethyluracil, 5-(carboxyhydroxymethyl)uracil, 
5-( methy laminomethyl )uracil, 5-( carboxymethy laminom-
ethy l )-uracil, 2-thiouracil, 5-methyl-2-thiouracil, 5-(2-bro-
movinyl)uracil, uracil-5-oxyacetic acid, uracil-5-oxyacetic 
acid methyl ester, pseudouracil, 1-methylpseudouracil, que-
osine, inosine, 1-methylinosine, hypoxanthine, xanthine, 
2-aminopurine, 6-hydroxyaminopurine, 6-thiopurine, and 
2,6-diaminopurine. 
The term "hybridization" as used herein refers to the pro-
cess of association of two nucleic acid strands to form an 
anti-parallel duplex stabilized by means ofhydrogen bonding 
between residues of the opposite nucleic acid strands. The 
terms "hybridizing" and "binding", with respect to poly-
Prior to describing the various embodiments, the following 
definitions are provided and should be used unless otherwise 
indicated. 
DEFINITIONS 
15 nucleotides, are used interchangeably and is meant the for-
mation of A-T and C-G base pairs between the nucleotide 
sequence of a fragment of a segment of a polynucleotide and 
a complementary nucleotide sequence of an oligonucleotide. 
In describing and claiming the disclosed subject matter, the 
following terminology will be used in accordance with the 20 
definitions set forth below. 
By complementary is meant that at the locus of each A, C, G 
or T (or U in a ribonucleotide) in the fragment sequence, the 
oligonucleotide sequenced has a T, G, C or A, respectively. 
The terms "oligonucleotide" and "polynucleotide" as used 
herein refer to any polyribonucleotide or polydeoxyribo-
nucleotide that may be unmodified RNA or DNA or modified 
RNA or DNA. Thus, for instance, polynucleotides as used 
herein refers to, among others, single- and double-stranded 
DNA, DNA that is a mixture of single- and double-stranded 
regions, single- and double-stranded RNA, and RNA that is 
mixture of single- and double-stranded regions, hybrid mol-
ecules comprising DNA and RNA that may be single-
stranded or, more typically, double-stranded or a mixture of 
single- and double-stranded regions. The terms "nucleic 
acid," "nucleic acid sequence," or "oligonucleotide" also 
encompass a polynucleotide as defined above. 
The term "nucleotide" as used herein refers to a sub-unit of 
a nucleic acid (whether DNA or RNA or an analogue thereof) 
which may include, but is not limited to, a phosphate group, 
a sugar group and a nitrogen containing base, as well as 
analogs of such sub-units. Other groups (e.g., protecting 
groups) can be attached to the sugar group and nitrogen 
containing base group. It will be appreciated that, as used 
herein, the terms "nucleotide" and "nucleoside" will include 
those moieties which contain not only the naturally occurring 
purine and pyrimidine bases, e.g., adenine (A), thymine (T), 
cytosine (C), guanine (G), or uracil (U), but also modified 
purine and pyrimidine bases and other heterocyclic bases 
which have been modified (these moieties are sometimes 
referred to herein, collectively, as "purine and pyrimidine 
bases and analogs thereof'). Such modifications include, e.g., 
diaminopurine and its deravitives, inosine and its deravitives, 
alkylated purines or pyrimidines, acylated purines or pyrim-
idines thiolated purines or pyrimidines, and the like, or the 
addition of a protecting group such as acetyl, difluoroacetyl, 
trifluoroacetyl, isobutyryl, benzoyl, 9-fluorenylmethoxycar-
bonyl, phenoxyacetyl, dimethylformamidine, N,N-diphenyl 
carbamate, or the like. The purine or pyrimidine base may 
also be an analog of the foregoing; suitable analogs will be 
known to those skilled in the art and are described in the 
pertinent texts and literature. Common analogs include, but 
are not limited to, 1-methyladenine, 2-methyladenine, 
The hybridized fragment/oligonucleotide is called a 
"duplex." 
The terms "hybridizing specifically to" and "specific 
25 hybridization" and "selectively hybridize to," as used herein 
refer to the binding, duplexing, or hybridizing of a nucleic 
acid molecule preferentially to a particular nucleotide 
sequence under stringent conditions. 
The terms "target" and "target analyte" as used herein refer 
30 to an oligonucleotide, peptide or polypeptide for which it is 
desired to detect. The target analyte for use in the methods 
herein disclosed may be an isolated oligonucleotide, peptide 
or polypeptide, an oligonucleotide, peptide or polypeptide 
immobilized on a solid support, or in free solution. Altema-
35 tively, the target oligonucleotide, peptide or polypeptide may 
be on a cell surface, the cell being isolated from a plant or 
animal host, a cultured cell or a cell or population of cells in 
a tissue of a plant or animal. 
The term "complementary" as used herein refers to a suf-
40 ficient number in the oligonucleotide of complementary base 
pairs in its sequence to interact specifically (hybridize) with 
the target nucleic acid sequence to be amplified or detected. 
As known to those skilled in the art, a very high degree of 
complementarity is needed for specificity and sensitivity 
45 involving hybridization, although it need not be 100%. Thus, 
for example, an oligonucleotide that is identical in nucleotide 
sequence to an oligonucleotide disclosed herein, except for 
one base change or substitution, may function equivalently to 
the disclosed oligonucleotides. A "complementary DNA" or 
50 "cDNA" gene includes recombinant genes synthesized by 
reverse transcription of messenger RNA ("mRNA"). 
By "immobilized on a solid support" is meant that an 
oligonucleotide is attached to a substance at a particular loca-
tion in such a manner that the system containing the immo-
55 bilized fragment, primer or oligonucleotide may be subjected 
to washing or other physical or chemical manipulation with-
out being dislodged from that location. A number of solid 
supports and means of immobilizing nucleotide-containing 
molecules to them are known in the art; any of these supports 
60 and means may be used in the methods of this disclosure. 
N 6-methy !adenine, N 6-isopenty !adenine, 2-methy lthio-N 6-
isopenty ladenine, N,N-dimethyladenine, 8-bromoadenine, 
2-thiocytosine, 3-methylcytosine, 5-methylcytosine, 5-ethyl-
cytosine, 4-acetylcytosine, 1-methylguanine, 2-methylgua-
nine, 7-methylguanine, 2,2-dimethylguanine, 8-bromogua- 65 
nine, 8-chloroguanine, 8-aminoguanine, 8-methylguanine, 
8-thioguanine, 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 
The terms "probe" and "oligonucleotide probe" as used 
herein refer to oligonucleotides nucleic acid sequences of 
variable length used in the detection of identical, similar, or 
complementary nucleic acid sequences by hybridization. 
A "restriction enzyme" refers to an endonuclease (an 
enzyme that cleaves phosphodiester bonds within a poly-
nucleotide chain) that cleaves DNA in response to a recogni-
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ti on site on the DNA. The recognition site (restriction site) 
consists of a specific sequence of nucleotides typically about 
4-8 nucleotides long. 
The term "RNase HII" as used herein refers to Ribonu-
clease HII which is an endoribonuclease that preferentially 
nicks 5' to a ribonucleotide within the context of a DNA 
duplex. The enzyme leaves 5' phosphate and3' hydroxyl ends. 
RNase HII will also nick at multiple sites along the RNA 
portion of an Okazaki fragment. 
The term "reporter oligonucleotide" as used herein refers 10 
to an oligonucleotide having a fluorophore moiety and a 
quencher moiety attached thereto. The term "molecular bea-
con" and "oligonucleotide molecular beacon" as used herein 
refer to a form of a reporter oligonucleotide having a fluoro-
phore- and quencher-labeled stem-loop structured oligode- 15 
oxyribonucleotide that is widely used for real-time detection 
of specific RNA/DNA sequences. In the stem-loop confor-
mation, a fluorophore is brought close to the quencher 
enabling efficient fluorescent quenching. Hybridization to a 
complementary DNA/RNA target switches the molecular 20 
beacon conformation to elongated, which is accompanied by 
the fluorescence increase. 
The term "fluorophore" as used herein refers to any 
reporter group whose presence can be detected by its light 
absorbing or light emitting properties. For example, Cy5 is a 25 
reactive water-soluble fluorescent dye of the cyanine dye 
family. Cy5 is fluorescent in the red region (about 650 to 
about 670 nm). It may be synthesized with reactive groups on 
either one or both of the nitrogen side chains so that they can 
be chemically linked to either nucleic acids or protein mo!- 30 
ecules. Labeling is done for visualization and quantification 
purposes. Cy5 is excited maximally at about 649 nm and 
emits maximally at about 670 nm, in the far red part of the 
spectrum; quantum yield is 0.28. FW=792. Suitable fluoro-
phores (chromes) for the probes of the disclosure may be 35 
selected from, but not intended to be limited to, fluorescein 
isothiocyanate (FITC, green), cyanine dyes Cy2, Cy3, Cy3.5, 
Cy5, Cy5 .5 Cy7, Cy7 .5 (ranging from green to near-infrared), 
Texas Red, and the like. Derivatives of these dyes for use in 
the embodiments of the disclosure may be, but are not limited 40 
to, Cy dyes (Amersham Bioscience), Alexa Fluors (Molecu-
lar Probes Inc.,), HILYTE® Fluors (AnaSpec ), andDYLITE0 
Fluors (Pierce, Inc). 
The term "aptamer" as used herein is an isolated nucleic 
acid molecule that binds with high specificity and affinity to a 45 
target, such as a protein. An aptamer is a three dimensional 
structure held in certain conformation( s) that provides chemi-
cal contacts to specifically bind its given target. Although 
aptamers are nucleic acid based molecules, there is a funda-
mental difference between aptamers and other nucleic acid 50 
molecules such as genes and mRNA. In the latter, the nucleic 
acid structure encodes information through its linear base 
sequence and thus this sequence is of importance to the func-
tion of information storage. In complete contrast, aptamer 
function, which is based upon the specific binding of a target 55 
molecule, is not entirely dependent on a conserved linear base 
sequence (a non-coding sequence), but rather a particular 
secondary /tertiary/ quaternary structure. Any coding potential 
that an aptamer may possess is entirely fortuitous and plays 
no role whatsoever in the binding of an aptamer to its cognate 60 
target. 
10 
nonfluorescent aromatic molecules that prevent the emission 
of fluorescence when they are physically near a fluorophore. 
The quencher can also be, but is not limited to, a fluorescent 
molecule, for example TAMRA (carboxytetramethyl-
rhodamine ). When the quencher is a fluorescent dye, its fluo-
rescence wavelength is typically substantially different from 
that of the reporter dye and the quencher fluorescence is 
usually not monitored during an assay. 
The terms "quench" or "quenches" or "quenching" or 
"quenched" as used herein refer to reducing the signal pro-
duced by a molecule. It includes, but is not limited to, reduc-
ing the signal produced to zero or to below a detectable limit. 
Hence, a given molecule can be "quenched" by, for example, 
another molecule and still produce a detectable signal albeit 
the size of the signal produced by the quenched molecule will 
be smaller when the molecule is quenched than when the 
molecule is not quenched. 
The term "solid support" is used herein refers to any 
insoluble and inert inorganic or organic material, preferably 
having a large surface area to which surface organic mol-
ecules can be attached through bond formation or absorbed 
through electronic or static interactions. Representative 
examples of a "solid support" in context with the present 
invention are silicates, such as Si02 resin, including, but not 
limited to, ion-exchange resins, glass, dextranes, celluloses or 
hydrophilic or hydrophobic polymers. 
Further definitions are provided in context below. Unless 
otherwise defined, all technical and scientific terms used 
herein have the same meaning as commonly understood by 
one of ordinary skill in the art of molecular biology. Although 
methods and materials similar or equivalent to those 
described herein can be used in the practice or testing of the 
present disclosure, suitable methods and materials are 
described herein. 
DESCRIPTION 
Generally, the assay system of the disclosure is composed 
of two short synthetic oligonucleotide probes (stands a and ~ 
as shown, for example, in FIG. 1), a reporter oligonucleotide 
labeled with both a fluorophore- and quencher (FIG. 1), and a 
DNA processing enzyme, or a nucleic acid processing activ-
ity catalyzed by a region of at least one of the two oligonucle-
otide probes. Both strands a and ~ contain at least one nucle-
otide sequence region complementary to a region or regions 
of the reporter oligonucleotide (reporter binding arms), and at 
least one nucleotide sequence region complementary to at 
least one region of the analyte ( analyte binding arms). In the 
presence of a target analyte such as, but not limited to, a 
nucleic acid, strands a and ~' the reporter oligonucleotide, 
and the analyte form a quadripartite complex. This complex 
can be specifically recognized by a DNA processing enzyme, 
a ribozyme, or deoxyribozyme (generated by the nucleotide 
sequence and the conformation thereof of at least one of the 
oligonucleotide probes) and which recognizes a specific site 
in the reporter oligonucleotide and catalyzes a reaction cleav-
ing the oligonucleotide and separation of two different mol-
ecules, each bearing the fluorophore or the quencher, but not 
both, as (FIG. 1, right). The resultant increase in fluorescence 
can be quantitatively detected by a conventional fluorimeter. 
The terms "fluorescence quencher" or "quencher" as used 
herein refer to a molecule that interferes with the fluorescence 
emitted by a fluorophore. This quencher can be selected from 
non-fluorescent aromatic molecules, to avoid parasitic emis-
sions. Exemplary quenchers include, but are not limited to, 
such as a Dabsyl or a BLACK HOLE QUENCHER® that are 
High specificity for a target analyte of the probe can be 
predetermined by independent or semi-independent hybrid-
ization of the analyte-binding arms of stands a and ~ to the 
65 analyte. Each arm can form a short hybrid with the analyte 
that is sensitive to a minor variation such as single base 
mispairing. 
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It is contemplated that in certain embodiments, a single 
analyte molecule such as an oligonucleotide can accommo-
date several quadripartite complexes, each of which can be 
processed by enzyme cleavage to resulting in a fluorophore 
and/or quencher release, thereby increasing sensitivity of the 
assay, or able to detect a plurality of nucleotide sequence 
variations within the single analyte molecule. 
12 
dimensional configuration of the nucleotide sequence of one 
of the two oligonucleotide probes. While it is contemplated 
that each of the oligonucleotide probes can independently 
form a ribozyme or a deoxyribozyme from the configuration 
of the reporter oligonucleotide-binding arms, it is not within 
the scope of the embodiments of the present disclosure forthe 
ribozyme or deoxyribozyme to result from interaction of the 
two probes with each other. 
In the systems as encompassed by the present disclosure, 
10 two oligonucleotide probes that can be made of DNA or RNA, 
or a combination of both. Each strand of the DNA or RNA 
The reporter oligonucleotide does not interact directly with 
the analyte and is, therefore, independent of the analyte 
sequence. Accordingly, it is possible to optimize the reporter 
oligonucleotide for use as a universal reporter not limited by 
the nature of the target analyte. The reporter oligonucleotide 
can be costly to synthesize due to the attachment reactions to 
link a fluorophore and the quencher to the beacon. A universal 
reporter can substantially reduce the cost of the multiplex 15 
assay systems of the disclosure. Embodiments of the systems 
probe has a customized fragment that has sequence comple-
mentarity to a selected target analyte (the analyte-binding 
arm), and a region having sequence complementarity to a 
region of a reporter oligonucleotide such as, but not limited 
to, a molecular beacon. The analyte-binding and reporter-
of the present disclosure are shown in Examples 1-9 below. 
The desired oligonucleotide probes can be defined, synthe-
sized, and purified my methods well known in the art. Attach-
ment of both a fluorophore and a fluorescence quencher to the 20 
universal reporter oligonucleotide are also well known in the 
art. 
binding arms optionally may be connected to each other by a 
linker. It is further contemplated that the oligonucleotide 
probes can have additional nucleotide sequences added to one 
or both of the free ends of each strand of the probe and which 
are complementary to, and can hybridize with, a region of the 
respective strand to form a stem-loop structure. These addi-
tional stem-loop-forming sequences are termed structure sta-
bilization arms (SSA) (see below). 
In the embodiments of the disclosure, it is contemplated 
that the two oligonucleotide probes may hybridize through 
their respective analyte-binding arms with a target analyte. 
While the targeted analyte can be advantageously a nucleic 
acid sequence, it is considered within the scope of the disclo-
Embodiments of the present disclosure, therefore, encom-
pass a PCR-free assay system that allows fluorescent detec-
tion of specific target analytes, including, but not limited to, 25 
specific nucleotide sequences, with high selectivity and sen-
sitivity. The advantages of the assay over currently available 
approaches include, but are not limited to, discrimination of 
signal nucleotide substitution in an analyzed nucleic acid 
with accuracy even at ambient temperatures, reduced detec-
tion limits comparable to enzymatic amplification, and lower 
costs per assay since only two short unmodified oligonucle-
otides are synthesized for each new analyte sequence, while 
30 sure for the analyte to be any biomolecule that may specifi-
cally bind to the analyte-binding arms of a pair of oligonucle-
otide probes, including, but not limited to, a peptide, a 
polypeptide, the glycosylated variants thereof, and the like, 
wherein the analyte-binding arms may be an aptamer. Ana-all other reagents are analyte independent and, therefore, can 
be obtained in bulk amount and utilized efficiently. In par-
ticular, the systems of the present disclosure provide an 
amplification of the detected fluorescent signal by allowing 
repeated formation of quencher-dissociated fluorophores. 
The systems of the present disclosure, accordingly, com-
prise two oligonucleotide probes, each probe comprising an 
analyte-binding arm, the nucleotide sequence of which may 
be selected to specifically bind to a target analyte, and a 
reporter oligonucleotide-binding arm, the sequence of which 
may specifically bind to a region within the nucleotide 
sequence of a reporter oligonucleotide. The systems of the 
present disclosure further comprise a reporter oligonucle-
otide having regions of nucleotide sequence complementary 
to the sequences of the reporter oligonucleotide-binding arm 
of the oligonucleotide probes. The target analyte nucleotide 
sequences (or regions of a peptide or polypeptide target ana-
lyte) selected for binding to the analyte-binding arms of the 
two oligonucleotide probes are chosen so as to place the two 
probe molecules in sufficiently close to one another to allow 
an interaction between the reporter-binding arms of both of 
the probes and the complementary regions of the reporter 
oligonucleotide itself (and thereby generating a "binary 
probe"). 
35 lytes may be a component of, or isolated from a biological 
source, including, but not limited to, a eukaryotic cell or 
tissue, a prokaryotic organism such as a bacterium or virus, or 
any other analyte to which the sequences of the pair of oligo-
nucleotides may specifically bind. Nucleic acid target ana-
40 lytes can be, but are not limited to, a DNA strand, an RNA 
strand, a nucleic acid double helix, and the like. 
The reporter oligonucleotide of the systems of the disclo-
sure comprises two nucleic acid sequences that can hybridize 
to the reporter oligonucleotide-binding arms of a pair of oli-
45 gonucleotide probes. Attached to the reporter oligonucleotide 
are a fluorophore and a quencher. In the absence of binding to 
the oligonucleotide probes, the reporter oligonucleotide pref-
erentially assumes a configuration, such as a stem-loop struc-
ture, where the fluorophore and the quencher are brought into 
50 close proximity, whereupon the quencher suppresses fluores-
cence emission by the fluorophore if irradiated by incident 
excitor light. 
In the systems provided by the disclosure, the reporter 
oligonucleotide may be, but is not limited to, a deoxyribo-
55 nucleic acid that may have a stem-loop conformation forming 
a molecular beacon. Although most molecular beacons are 
DNA oligonucleotides, there is no technical obstacle to mak-
ing molecular beacons that are RNA or chimeras of DNA and The reporter oligonucleotides of the disclosure also 
include a fluorophore and a quencher moiety that may be 
located at the extreme ends of the reporter oligonucleotide 60 
molecule, or internally but separated such that ifthe reporter 
oligonucleotide is elongated there is no interaction between 
the fluorophore and the quencher. 
RNA for use in the new binary RNA oligonucleotide probes. 
In some embodiments, the reporter may include one or 
more ribonucleotides that provide cleavable sites within the 
reporter nucleotide sequence. However, it is contemplated 
that the reporter oligonucleotide may comprise a nucleotide 
sequence that, when hybridized with a complementary In the embodiments of the present disclosure, the reporter 
oligonucleotides further include at least one cleavable site 
that may be specifically cleaved by a protein enzyme, or by a 
ribozyme or a deoxyribozyme that is formed by the three-
65 sequence in the reporter-binding-arm of an oligonucleotide 
probe, forms a site that can be recognized and specifically 
cleaved by an enzyme. 
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otide probes about 12 to about 40 nucleotides long. The 
analyte itself can be of any length from 12-40, to many thou-
sand nucleotides. Analyte-binding arms of about 10 nucle-
otides are advantageous because a combined length of about 
20 nucleotides of a target analyte will cover most unique 
sequences in the genome. Analyte-binding arms that recog-
nize an analyte region with a combined length longer than 
about 20 nucleotides may have increased sensitivity. 
Linkers 
The analyte-binding- and reporter oligonucleotide-binding 
arms of anoligonucleotideprobe of the systems of the present 
disclosure may be, but not necessarily, separated by a linker. 
For example, but not intended to be limiting, such a linker 
may be a stretch of nucleotides. Such a linker may, when the 
The probe can be customized for any fluorophore includ-
ing, but not limited to, FAM, TAMRA, Dy 750, HEX™, JOE, 
TET™, Texas Red-X, Alexa Fluor Dyes, Bodipy Dyes, CY 
Dyes, Rhodanine, dyes, WellRED Dyes, MAX, and TEX 
613; and for any quencher including, but not limited to, black 
hole quenchers, Iowa Black Quenchers, and DABCYL. It is 
within the scope of the disclosure, however, for a plurality of 
systems to be combined, wherein a different target analyte is 
detectable by each system and each system incorporates a 
different and distinguishable fluorophore for the simulta- 10 
neous detection of multiple analytes in a single test sample. 
Reporter oligonucleotide-binding arms on each strand are 
typically 3-20 nucleotides long, but routine experimentation 
based on the reporter oligonucleotide will determine the opti-
mum length. 15 oligonucleotide probes are bound to a target analyte, hybrid-
ize to the linker of the second of the two pro bes bound to a 
target analyte, whereupon the two linkers may hybridize to 
form a double helix. However, it is also possible for the linker 
For example, and not intended to be limiting, at least one 
nucleotide sequence, when hybridized with a complementary 
sequence in the reporter-binding-arm of an oligonucleotide 
probe, forms a site that can be recognized and specifically 
cleaved by a restriction endonuclease. In another embodi- 20 
ment, the nucleotide sequence, when hybridized with a 
complementary sequence in the reporter-binding-arm of an 
oligonucleotide probe, can form a site that includes a ribo-
nucleotide and which can be specifically cleaved by RNase 
HII. In all embodiments of the systems of the present disclo- 25 
sure, however, it is contemplated that the reporter oligonucle-
otide will have at least one cleavable site located between the 
fluorophore and the quencher. 
to be merely one or two nucleotides that cannot form a duplex 
double-helix, nor bind to the target analyte. It is further con-
templated that the linker of an oligonucleotide probe may be, 
but not limited to, a flexible triethylene glycol linker. 
Also within the scope of the disclosure are systems where 
one of the analyte-detecting oligonucleotide probes of a pair 
of such probes is immobilized to a solid substrate. The present 
disclosure therefore encompasses probes according to the 
present disclosure that are immobilized on a solid or flexible 
support, such as paper, nylon or other type of membrane, 
filter, chip, glass slide, microchips, microbeads, or any other In the assays using the systems and methods of the present 
disclosure, a test sample suspected of having a target analyte 
is contacted with a pair of oligonucleotide probes having 
analyte-binding arms that can specifically bind to the target 
analyte, and which may then bind to the analyte under the 
appropriate conditions. The reporter oligonucleotide-binding 
arms of the bound oligonucleotide probes can then preferen-
tially bind to the corresponding complementary regions 
within the reporter oligonucleotide to form a quaternary, or 
quadripartite, complex such as illustrated in FIGS. 1, 3, 6-11. 
Initially, complexing of the reporter oligonucleotide with the 
oligonucleotide probes will elongate the reporter oligonucle-
otide, thereby dissociating the fluorophore and the quencher 
from each other and allowing, with a suitable wavelength of 
incident light, to generate a first level of fluorescence emis-
sion intensity. However, by then providing the system with a 
protein enzyme that specifically binds to, and cleaves, the 
cleavable site(s) of the reporter oligonucleotide, a frag-
ment(s) of the reporter oligonucleotide bearing the fluoro-
phore (or quencher, or both the fluorophore and the quencher) 
is released from the quadripartite complex, which then dis-
sociates to reform with a new and uncleaved reporter oligo-
nucleotide molecule to renew the cycle. Accordingly, the 
detectable fluorescence intensity becomes amplified, provid-
ing increased sensitivity of the assay to the target analyte. 
In one embodiment of the assay system of the disclosure, 
however, the protein enzyme that can be used to specifically 
cleave the reporter oligonucleotide can be replaced by at least 
one of the reporter oligonucleotide-binding arms of the quad-
ripartite complex assuming a configuration of a ribozyme (if 
the oligonucleotide-binding arm is an RNA sequence) or a 
deoxyribozyme (if the oligonucleotide-binding arm is an 
RNA sequence) that can specifically cleave a site within the 
reporter oligonucleotide sequence that includes a ribonucle-
otide, as illustrated in FIG. 11, for example. 
For optimum selectivity, for example ofSNPs, the analyte-
binding arm of each strand of the probe ranges from about 6 
to about 20 nucleotides in length, which makes the total 
analyte fragment region recognizable by a pair of oligonucle-
30 such matrix, all of which are within the scope of this disclo-
sure. The probe of this form is now called a "DNA chip". 
These DNA chips can be used for analyzing the SNPs of the 
present disclosure. The present disclosure further encom-
passes arrays or microarrays of nucleic acid molecules that 
35 are based on one or more of the sequences described herein. 
As used herein "arrays" or "microarrays" refers to an array of 
distinct polynucleotides or oligonucleotides synthesized on a 
solid or flexible support, such as paper, nylon or other type of 
membrane, filter, chip, glass slide, or any other suitable solid 
40 support. In one embodiment, the microarray is prepared and 
used according to the methods and devices described in U.S. 
Pat. Nos. 5,446,603; 5,545,531; 5,807,522; 5,837,832; 5,874, 
219; 6,114,122; 6,238,910; 6,365,418; 6,410,229; 6,420,114; 
6,432,696; 6,475,808 and 6,489,159 and PCT Publication 
45 No. WO 01/45843 A2, the disclosures of which are incorpo-
rated by reference in their entireties. 
Compositions and kits for the detection of analytes: The 
oligonucleotide primers and probes of the present disclosure 
have commercial applications in diagnostic kits for the detec-
50 ti on of such as SNPs in biological specimens. A kit according 
to the disclosure may comprise any of the oligonucleotide 
primers or probes according to the disclosure and preferable 
includes packaging and instructions for the use thereof. An 
SNP detection kit may also include a lysing buffer for lysing 
55 cells contained in the specimen. 
One aspect of the disclosure, therefore, encompasses 
embodiments of a system for detecting a target analyte, the 
system comprising: (a) a first oligonucleotide probe compris-
ing: (i) at the 5'-terminus thereof, a reporter oligonucleotide-
60 binding arm having a nucleotide sequence complementary to 
the nucleotide sequence of a first region of a reporter oligo-
nucleotide; and (ii) at the 3'-terminus thereof, an analyte-
binding arm having a nucleotide sequence characterized as 
selectively binding to a first region of a target analyte; (b) a 
65 second oligonucleotide probe comprising: (i) at the 3'-termi-
nus thereof, a reporter oligonucleotide-binding arm having a 
nucleotide sequence complementary to the nucleotide 
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sequence of a second region of a reporter oligonucleotide; and 
(ii) at the 5'-terminus thereof, an analyte-binding arm having 
a nucleotide sequence characterized as selectively binding to 
a second region of a target analyte; ( c) a reporter oligonucle-
otide comprising: (i) a first region having a nucleotide 
sequence complementary to the reporter oligonucleotide-
binding arm of the first oligonucleotide probe; (ii) a second 
region having a nucleotide sequence complementary to the 
reporter oligonucleotide-binding arm of the second oligo-
nucleotide probe; (iii) a fluorophore and a quencher disposed 
on the reporter oligonucleotide whereby the fluorophore and 
quencher interact in the absence of a target analyte to quench 
fluorescence generated by the fluorophore; and (iv) a cleav-
able site disposed between the fluorescent label and the 
quencher, wherein the cleavable site is characterized as cleav-
able by a protein enzyme or a region of the first or the second 
oligonucleotide probe; and (d) an oligonucleotide-cleaving 
agent characterized as specifically cleaving the cleavable site 
of the reporter oligonucleotide. 
In embodiments ofthis aspect of the system of the disclo-
sure, the oligonucleotide-cleaving agent can be selected from 
the group consisting of an enzyme, a ribozyme, and a deox-
yribozyme, and the ribozyme, and a deoxyribozyme can be 
optionally derived from a configuration of a region of the first 
oligonucleotide probe, the second oligonucleotide probe, or 
both the first and the second oligonucleotide probe. 
In embodiments ofthis aspect of the system of the disclo-
sure, the cleavable site of the reporter oligonucleotide can 
comprise a ribonucleotide. 
In embodiments ofthis aspect of the system of the disclo-
sure, the reporter oligonucleotide-binding arm of at least one 
oligonucleotide probe can comprise a nucleotide sequence 
that provides a site in the reporter oligonucleotide specifically 
cleavable by a restriction endonuclease when said oligonucle-
otide probe is hybridized to the reporter oligonucleotide, and 
the oligonucleotide-cleaving agent is said restriction endonu-
clease. 
In embodiments ofthis aspect of the system of the disclo-
sure, the oligonucleotide-cleaving agent can be an enzyme 
selected from the group consisting of: a restriction endonu-
clease, an RNase H, a Flap-endonuclease-1 (FEN-1), and a 
DNA glycosylase. 
In embodiments ofthis aspect of the system of the disclo-
sure, the reporter oligonucleotide-binding arm of at least one 
oligonucleotide probe can comprise a nucleotide sequence 
configured as a deoxyribozyme oligonucleotide-cleaving 
agent capable of specifically cleaving a site in the reporter 
oligonucleotide when the oligonucleotide probe is hybridized 
to the reporter oligonucleotide and to a target analyte. 
In embodiments ofthis aspect of the system of the disclo-
sure, the at least one of the first oligonucleotide probe and the 
second oligonucleotide probe can further comprise a linker 
connecting the analyte-binding arm and the reporter oligo-
nucleotide-binding arm of said oligonucleotide probe. 
In embodiments ofthis aspect of the system of the disclo-
sure, the reporter oligonucleotide can be a molecular beacon 
characterized as having a stem-loop configuration in the 
absence of a target analyte. 
In embodiments ofthis aspect of the system of the disclo-
sure, at least one of the fluorophore and the quencher can be 
attached to the reporter oligonucleotide at the 5' or the 3' 
terminus thereof. 
In embodiments ofthis aspect of the system of the disclo-
sure, the system can further comprise a target analyte and 
wherein the analyte, the first and second oligonucleotide 
probes, and the reporter oligonucleotide form a quadripartite 
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complex, thereby providing a configuration of the cleavable 
site of the reporter oligonucleotide allowing said site to be 
cleaved. 
In embodiments ofthis aspect of the system of the disclo-
sure, the nucleotide sequences of the analyte-binding arms of 
the first and the second oligonucleotide probes can be inde-
pendently selected to specifically bind to a target analyte 
comprising a deoxyribonucleotide sequence, a ribonucle-
otide sequence, a double-stranded nucleic acid, a peptide, a 
10 polypeptide, or a variant thereof. 
In embodiments ofthis aspect of the system of the disclo-
sure, the first or the second oligonucleotide probe can be 
tethered to a substrate. 
In embodiments ofthis aspect of the system of the disclo-
15 sure, the system can further comprise a plurality of oligo-
nucleotide probe pairs, each probe pair comprising a first 
oligonucleotide probe and a second oligonucleotide probe. 
In embodiments ofthis aspect of the system of the disclo-
sure, the plurality of oligonucleotide probe pairs can selec-
20 tively bind to a plurality of sites of a single target analyte. 
In embodiments ofthis aspect of the system of the disclo-
sure, the plurality of oligonucleotide probe pairs can selec-
tively bind to a plurality of target analytes. 
In embodiments ofthis aspect of the system of the disclo-
25 sure, one oligonucleotide probe in each probe pair can be 
tethered to a substrate. 
In embodiments ofthis aspect of the system of the disclo-
sure, the oligonucleotide probe in each probe pair tethered to 
a substrate can be disposed on the substrate as an array. 
30 Another aspect of the disclosure encompasses embodi-
ments of method of identifying a target nucleotide sequence 
comprising the steps of: (i) obtaining a test sample; (ii) form-
ing a reaction mix by combining the test sample with: (a) a 
first oligonucleotide probe comprising: (i) at the 5'-terminus 
35 thereof, a reporter oligonucleotide-binding arm having a 
nucleotide sequence complementary to the nucleotide 
sequence of a first region of a reporter oligonucleotide; and 
(ii) at the 3'-terminus thereof, an analyte-binding arm having 
a nucleotide sequence characterized as selectively binding to 
40 a first region of a target analyte; (b) a second oligonucleotide 
probe comprising: (i) at the 3'-terminus thereof, a reporter 
oligonucleotide-binding arm having a nucleotide sequence 
complementary to the nucleotide sequence of a second region 
of a reporter oligonucleotide; and (ii) at the 5'-terminus 
45 thereof, an analyte-binding arm having a nucleotide sequence 
characterized as selectively binding to a second region of a 
target analyte; ( c) a reporter oligonucleotide comprising: (i) a 
first region having a nucleotide sequence complementary to 
the reporter oligonucleotide-binding arm of the first oligo-
50 nucleotide probe; (ii) a second region having a nucleotide 
sequence complementary to the reporter oligonucleotide-
binding arm of the second oligonucleotide probe; (iii) a fluo-
rophore and a quencher disposed on the reporter oligonucle-
otide whereby said fluorophore and quencher interact in the 
55 absence of a target analyte to quench fluorescence generated 
by the fluorophore; and (iv) a cleavable site disposed between 
the fluorescent label and the quencher, wherein the cleavable 
site is characterized as cleavable by a protein enzyme or a 
region of the first or the secondoligonucleotide probe, and ( d) 
60 an oligonucleotide-cleaving agent characterized as specifi-
cally cleaving the cleavable site of the reporter oligonucle-
otide; under conditions suitable for the formation of a quad-
ripartite complex between the analyte-binding arms of the 
first and the second oligonucleotide probes, a target analyte in 
65 the test sample, and the reporter oligonucleotide, thereby 
exposing a cleavable site of the reporter oligonucleotide for 
cleavage; (iii) allowing cleavage of a cleavable site of the 
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reporter oligonucleotide, thereby releasing the fluorophore, 
the quencher, or both the fluorophore and the quencher, from 
the quadripartite complex; (iv) illuminating the reaction mix 
at a wavelength suitable for inducing a fluorescent emission 
by the fluorophore; and ( v) detecting the fluorescence emitted 
by the fluorophore, thereby detecting the presence of the 
target analyte in the sample. 
In embodiments ofthis aspect of the system of the disclo-
sure, the oligonucleotide-cleaving agent can be selected from 
the group consisting of an enzyme, a ribozyme, and a deox-
yribozyme, and the ribozyme, and a deoxyribozyme can be 
optionally derived from a configuration of a region of the first 
oligonucleotide probe, the second oligonucleotide probe, or 
both the first and the second oligonucleotide probe. 
In embodiments ofthis aspect of the system of the disclo-
sure, the cleavable site of the reporter oligonucleotide can 
comprise a ribonucleotide. 
In embodiments ofthis aspect of the system of the disclo-
sure, the reporter oligonucleotide-binding arm of at least one 
oligonucleotide probe can comprise a nucleotide sequence 
that provides a site in the reporter oligonucleotide specifically 
cleavable by a restriction endonuclease when said oligonucle-
otide probe is hybridized to the reporter oligonucleotide. 
In embodiments ofthis aspect of the system of the disclo-
sure, the cleavable site of the reporter oligonucleotide when in 
the presence of a target analyte can be cleavable by an enzyme 
selected from the group consisting of: a restriction endonu-
clease, an RNase H, a Flap-endonuclease-1 (FEN-1), and a 
DNA glycosylase. 
In embodiments ofthis aspect of the system of the disclo-
sure, the reporter oligonucleotide-binding arm of at least one 
oligonucleotide probe can comprise a nucleotide sequence 
configured as a deoxyribozyme capable of specifically cleav-
ing a site in the reporter oligonucleotide when the oligonucle-
otide probe is hybridized to the reporter oligonucleotide and 
to a target analyte. 
In embodiments ofthis aspect of the system of the disclo-
sure, the first oligonucleotide probe and the second oligo-
nucleotide probe the analyte-binding arm and the reporter 
oligonucleotide-binding arm thereof can be connected by a 
linker. 
In embodiments ofthis aspect of the system of the disclo-
sure, the reporter oligonucleotide can be a molecular beacon 
and can be characterized as having a stem-loop configuration 
in the absence of a target analyte. 
In embodiments ofthis aspect of the system of the disclo-
sure, the at least one of the fluorophore and the quencher can 
be attached to the reporter oligonucleotide at the 5' or the 3' 
terminus thereof. 
In embodiments ofthis aspect of the system of the disclo-
sure, the method can further comprise a target analyte 
wherein the analyte, the first and second oligonucleotide 
probes, and the reporter oligonucleotide can form a quadri-
partite complex, thereby providing a configuration of the 
cleavable site of the reporter oligonucleotide allowing said 
site to be cleaved. 
In embodiments ofthis aspect of the system of the disclo-
sure, the nucleotide sequences of the analyte-binding arms of 
the first and the second oligonucleotide probes can be inde-
pendently selected to specifically bind to a target analyte 
comprising a deoxyribonucleotide sequence, a ribonucle-
otide sequence, a double-stranded nucleic acid, a peptide, a 
polypeptide, or a variant thereof. 
In embodiments ofthis aspect of the system of the disclo-
sure, the first or the second oligonucleotide probe can be 
tethered to a substrate. 
18 
In embodiments ofthis aspect of the system of the disclo-
sure, the method can comprise a plurality of oligonucleotide 
probe pairs, each probe pair comprising a first oligonucle-
otide probe and a second oligonucleotide probe. 
In embodiments ofthis aspect of the system of the disclo-
sure, the plurality of oligonucleotide probe pairs can selec-
tively bind to a plurality of sites of a single target analyte. 
In embodiments ofthis aspect of the system of the disclo-
sure, the plurality of oligonucleotide probe pairs can selec-
lO tively bind to a plurality of target analytes. 
15 
In embodiments ofthis aspect of the system of the disclo-
sure, one oligonucleotide probe in each probe pair can be 
tethered to a substrate. 
In embodiments ofthis aspect of the system of the disclo-
sure, the oligonucleotide probe in each probe pair tethered to 
a substrate can be disposed on the substrate as an array. 
Yet another aspect of the disclosure encompasses embodi-
ments of a kit comprising: (a) a first oligonucleotide probe 
20 comprising: (i) at the 5'-terminus thereof, a reporter oligo-
nucleotide-binding arm having a nucleotide sequence 
complementary to the nucleotide sequence of a first region of 
a reporter oligonucleotide; (ii) at the 3'-terminus thereof, an 
analyte-binding arm having a nucleotide sequence character-
25 ized as selectively binding to a first region of a target analyte; 
and (iii) optionally, a linker region covalently linking the 
reporter oligonucleotide-binding arm and the analyte-bind-
ing arm; (b) a second oligonucleotide probe comprising: (i) at 
the 3'-terminus thereof, a reporter oligonucleotide-binding 
30 arm having a nucleotide sequence complementary to the 
nucleotide sequence of a second region of a reporter oligo-
nucleotide; (ii) at the 5'-terminus thereof, an analyte-binding 
arm having a nucleotide sequence characterized as selectively 
binding to a second region ofa target analyte; and (iii) option-
35 ally, a linker region covalently linking the reporter oligo-
nucleotide-binding arm and the analyte-binding arm; (c) a 
reporter oligonucleotide comprising: (i) a first region having 
a nucleotide sequence complementary to the reporter oligo-
nucleotide-binding arm of the first oligonucleotide probe; (ii) 
40 a second region having a nucleotide sequence complemen-
tary to the reporteroligonucleotide-binding arm of the second 
oligonucleotide probe; (iii) a fluorophore and a quencher 
disposed on the reporter oligonucleotide whereby said fluo-
rophore and quencher interact in the absence of a target ana-
45 lyte to quench fluorescence generated by the fluorophore; and 
(iv) a cleavable site disposed between the fluorescent label 
and the quencher, wherein the cleavable site is characterized 
as cleavable by a protein enzyme or a region of the first or the 
second oligonucleotide probe; or a plurality of oligonucle-
50 otide probe pairs, each probe pair comprising a first oligo-
nucleotide probe and a second oligonucleotide probe, 
wherein the plurality of oligonucleotide probe pairs selec-
tively binds to a plurality of sites of a single target analyte or 
to a plurality of target analytes, and wherein one oligonucle-
55 otide probe in each probe pair optionally is tethered to a 
substrate, and optionally disposed on the substrate as an 
array; ( d) optionally, an oligonucleotide-cleaving agent char-
acterized as specifically cleaving the cleavable site of the 
reporter oligonucleotide; and ( e) packaging and instructions 
60 for the use of the kit to detect a target analyte in a test sample. 
In embodiments ofthis aspect of the system of the disclo-
sure, the oligonucleotide-cleaving agent can be selected from 
the group consisting of an enzyme, a ribozyme, and a deox-
yribozyme, and the ribozyme, and a deoxyribozyme are 
65 optionally derived from a configuration of a region of the first 
oligonucleotide probe, the second oligonucleotide probe, or 
both the first and the second oligonucleotide probe. 
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In embodiments ofthis aspect of the system of the disclo-
sure, the reporter oligonucleotide-binding arm of at least one 
oligonucleotide probe can comprise a nucleotide sequence 
configured as a deoxyribozyme capable of specifically cleav-
ing a site in the reporter oligonucleotide when the oligonucle-
otide probe is hybridized to the reporter oligonucleotide and 
to a target analyte. 
In embodiments ofthis aspect of the system of the disclo-
sure, the reporter oligonucleotide can be a molecular beacon 
and is characterized as having a stem-loop configuration in 10 
the absence of a target analyte. 
In embodiments ofthis aspect of the system of the disclo-
sure, the oligonucleotide probe can be tethered to a substrate. 
The specific examples below are to be construed as merely 
illustrative, and not !imitative of the remainder of the disclo- 15 
sure in any way whatsoever. Without further elaboration, it is 
believed that one skilled in the art can, based on the descrip-
tion herein, utilize the present disclosure to its fullest extent. 
All publications recited herein are hereby incorporated by 
reference in their entirety. 20 
It should be emphasized that the embodiments of the 
present disclosure, particularly, any "preferred" embodi-
ments, are merely possible examples of the implementations, 
merely set forth for a clear understanding of the principles of 
the disclosure. Many variations and modifications may be 
made to the above-described embodiment(s) of the disclosure 
without departing substantially from the spirit and principles 
of the disclosure. All such modifications and variations are 
intended to be included herein within the scope of this dis-
closure, and the present disclosure and protected by the fol-
lowing claims. 
The following examples are put forth so as to provide those 
25 
30 
20 
molecular beacon (molecular beacon-binding arm) and a 
fragment complementary to a DNA analyte. In the presence 
of the analyte, the probe forms a quadripartite complex, in 
which BDP strands serve as adaptors to connect the analyte 
and the molecular beacon reporter. The molecular beacon-
binding arm of BDP strand ~ is complementary to the 
molecular beacon fragment, which contains a single ribo-
nucleotide embedded into DNA sequence. RNase HII recog-
nizes the ribonucleotide-containing duplex fragment and 
cleaves the phosphodiester bond at the 5'-end of the ribo-
nucleotide. As a result, the molecular beacon is hydrolyzed 
into two fragments, which dissociate from the quadripartite 
complex. The resulting tripartite complex of the analyte with 
two strands of Enz-BDPl can bind another molecule of 
molecular beacon from solution to form the complex, which 
is then recognized by the enzyme. Therefore, the signal 
amplification is achieved. 
TABLE 1 
The sequences of analyte HepC30 and 
oligonucleotides constituting Enz-BDPl 
HepC30 
Enz-BDPl 
strand a 
Enz-BDPl 
strand 13 
Molecular 
Beacon 1 
(MBl) 
5'-TGCCCCGGAGGTCTGTAGACCGTGCACC-3' 
(SEQ ID NO. · 1) 
5'-GACCATCTCAGACCTCCCGGG-3' 
(SEQ ID NO.· 2) 
5'-CACGGTCTACGTTCCTATAG-3' 
(SEQ ID NO.· 3) 
5'-F-CCGACTCACTAT~GGAAGAGATGGTCGG-Q-3' 
(SEQ ID NO.· 4)a 
asmall case indicates ribonucleotide 
35 F and Q designate the Fluorescein and Black Hole 1 quencher, 
respectively. 
of ordinary skill in the art with a complete disclosure and 
description of how to perform the methods and use the com-
positions and compounds disclosed and claimed herein. 
Efforts have been made to ensure accuracy with respect to 
numbers (e.g., amounts, temperature, etc.), but some errors 
and deviations should be accounted for. Unless indicated 
otherwise, parts are parts by weight, temperature is in ° C., 
and pressure is at or near atmospheric. Standard temperature 40 
and pressure are defined as 20° C. and 1 atmosphere. 
It should be noted that ratios, concentrations, amounts, and 
other numerical data may be expressed herein in a range 
format. It is to be understood that such a range format is used 
for convenience and brevity, and thus, should be interpreted in 45 
a flexible marmer to include not only the numerical values 
explicitly recited as the limits of the range, but also to include 
all the individual numerical values or sub-ranges encom-
passed within that range as if each numerical value and sub-
range is explicitly recited. To illustrate, a concentration range 50 
of"about 0.1 % to about 5%" should be interpreted to include 
not only the explicitly recited concentration of about 0.1 wt% 
to about 5 wt %, but also include individual concentrations 
(e.g., 1 %, 2%, 3%, and 4%) and the sub-ranges (e.g., 0.5%, 
1.1%,2.2%, 3.3%, and4.4%) within the indicated range. The 55 
term "about" can include ±1 %, ±2%, ±3%, ±4%, ±5%, ±6%, 
±7%, ±8%, ±9%, or ±10%, or more of the numerical value(s) 
being modified. 
Example 2 
Referring now to FIG. 2, another embodiment of the dis-
closure provides fluorescence enhancement of Enz-BDPl 
together with RNase HII in the presence or in the absence of 
the analyte HepC30. Reaction conditions: 10 nM molecular 
beacon 1, 100 nM strands a and~' 10 nM HepC30; 2U RNase 
HII; 20 mM Tris-HCI, pH 8.8; 10 mM (NH4 ) 2S04 , 10 mM 
KC!, 25 mM MgCI, 0.1 % Triton X-100; 30° C. 
Example 3 
Referring now to FIG. 3, another embodiment of the dis-
closure provides a design ofEnz-BDP2. The probe consists of 
a reporter oligonucleotide (in this example, but not limited 
thereto, a molecular beacon) and two DNA strands: strand a 
and strand~· Each of the strands contains a fragment comple-
mentary to the reporter oligonucleotide (reporter oligonucle-
otide-binding arm) and a fragment complementary to a DNA 
analyte. In the presence of the analyte, the probe forms a 
quadripartite complex, in which BDP strands serve as adap-
tors to connect the analyte and the reporter oligonucleotide. 
EXAMPLES 
Example 1 
One embodiment of the system of the present disclosure 
provides a molecular beacon (molecular beacon), which acts 
as a reporter, and two DNA strands: strand a and strand ~· 
Each of the strands contains a fragment complementary to 
60 Reporter oligonucleotide-binding arms of the BDP strands 
are complementary to two reporter oligonucleotide frag-
ments, each of which contains a single ribonucleotide embed-
ded into DNA sequence. RNase HII recognizes the duplex 
fragments and cleaves the phosphodiester bond at the 5' end 
65 of the ribonucleotide. As a result, reporter oligonucleotide is 
hydrolyzed into three fragments-the fluorophore-contain-
ing fragment, the middle fragment, and the quencher-contain-
US 8,859,266 B2 
21 
ing fragment, which dissociate from the quadripartite com-
plex. The resulting tripartite complex of the analyte with two 
strands of Enz-BDP2 can bind another molecule of the 
reporter oligonucleotide from solution to form the complex, 
which is then recognized by the enzyme. Therefore, the signal 
amplification is achieved. 
TABLE 2 
The sequences of analyte HepC40 
and oligonucleotides constituting Enz-BDP2 
HepC40 
Enz-BDP2 
strand a 
Enz-BDP2 
strand 13 
TTCATCGTCTCGCCGCAGTACCACTGGTTTGTGCAAGAAT 
(SEQ ID NO. · 5) 
GATCTATTGGTACTGCGGCGA 
(SEQ ID NO.· 6) 
GCACAAACCAGTGTATGTTAAC 
(SEQ ID NO. · 7) 
Molecular FAM-5'-CGCGTTAaCATACAAT~GATCGCG-BHQl 
Beacon 2 (SEQ ID NO.· 8)a 
(MB2) 
asmall case indicates ribonucleotide 
As shown in FIG. 4, fluorescence enhancement of Enz-
BDP2 in the presence of the analyte HepC40 (SEQ ID NO.: 5) 
with or without RNase HII. Reaction conditions: 10 nM 
molecular beacon 2 (MB2), 100 nM BDP2 (strands a and~) 
10nMHepC40; 2URNaseHII; 20mMTris-HCI, pH 8.8; 10 
mM (NH4 ) 2 S04 , 10 mM KC!, 25 mM MgCI, 0.1% Triton 
X-100; 30° C. 
As shown in FIG. 5, fluorescence enhancement of Enz-
BDP2 in the presence of the analyte HepC40 (SEQ ID NO.: 5) 
22 
reporter oligonucleotide in the absence of analyte, the 
reporter oligonucleotide is only cleaved when the targeted 
analyte is present and the oligonucleotide probes hybridize to 
both the reporter oligonucleotide and the analyte to form the 
quadripartite complex, followed by an increase in fluorescent 
intensity. 
Furthermore, the reporter oligonucleotide can form stem-
loop hairpin structure to minimize its interactions with 
strands a and ~ in the absence of the analyte. This assay is 
10 
adoptable to microarray format as described below. 
Example 6 
Exonuclease-based assay: The reporter oligonucleotide-
15 cleaving enzyme can be an exonuclease that removes a 5' or 
3'-end nucleotide. The reporter oligonucleotide will include a 
fluorophore and/or a quencher on 3' or 5' ends. FIG. 7 sche-
matically illustrates a fluorophore dye conjugated with either 
3' or 5' of the reporteroligonucleotide. When the quadripartite 
20 complex is formed (FIG. 7B) in the presence of the analyte, an 
exonuclease can cleave off the fluorophore-conjugated nucle-
otide, resulting in an increase in fluorescence emission. 
Furthermore, the reporter oligonucleotide can form stem-
loop hairpin structure to minimize its interactions with 
25 strands a and ~ in the absence of the analyte. This assay is 
adoptable to microarray format as described below. 
Example 7 
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as a function of the analyte concentration. Reaction condi-
tions: 10 nM universal molecular beacon 2 (MB2), 100 nM 
BDP2 (strands a and~), 0.1-5 nM HepC40; 2U RNase HII; 35 
20mMTris-HCl,pH8.8; 10mM(NH4 ) 2S04 , lOmMKCl,25 
mM MgCI, 0.1 % Triton X-100; 30° C., for 1 h. 
Flap endonuclease-based assay: One of the oligonucle-
otide probe strands (strand a in FIG. 8) can contain a stem-
loop structure resulting in the formation of an overhang struc-
ture, a "flap structure", in quadripartite complex formed in the 
presence of a target analyte (as shown in FIG. 8. Such a 
structure is a specific substrate for Flap-endonuclease-1 
(FEN-1) that cleaves a phosphodiester bond thereby liberat-
ing the fluorophore nucleotide. 
Example 4 
Furthermore, the oligonucleotide molecular beacon can 
form stem-loop hairpin structure to minimize its interactions 
40 with strands a and~ in the absence of the analyte. This assay 
is adoptable to microarray format as described below. RNase H-based binary probe assay: In this embodiment of 
the assay, the reporter oligonucleotide molecular beacon con-
tains one or more ribonucleotides between the fluorophore 
and quencher attachment sites, as shown in FIGS. 6 and 12. 
The quadripartite complex thus formed contains a DNA- 45 
RNA hybrid (circled) that is the substrate ofRNase HII. The 
enzyme cleaves the reporter oligonucleotide substrate, 
thereby releasing the fluorophore into solution. The single 
stranded oligonucleotide molecular beacon cannot be cleaved 
by RNase HII, which contributes to desirable low background 50 
fluorescence. 
Example 8 
DNA glycosylase-based assay: In this assay the oligo-
nucleotide molecular beacon has at least one irregular or 
mismatched-forming nucleotide (indicated as VF in FIG. 9). 
This nucleotide is conjugated with a fluorophore. The fluo-
rescence of the fluorophore is quenched by the closely located 
quencher moiety. Upon quadripartite complex formation, 
however, the double stranded fragment with the embedded 
"damaged" nucleotide is recognized by a specific DNA gly-
cosylase. Upon hydrolysis of the N-glucosidic bond (FIG. 9): 
the fluorescently-labeled nucleotide base is released into 
Furthermore, the oligonucleotide molecular beacon can 
form stem-loop hairpin structure to minimize its interactions 
with strands a and~ in the absence of the analyte. This assay 
is adoptable to microarray format as described below. 
Example 5 
55 solution. Possible glycosylases include, but are not limited to, 
uracil DNA glycosylases, 8-oxoguanine DNA glycosylase, 
3-methyadenine DNA glycosylas, T:G miss-pair DNA gly-
cosylase, and the like. 
Furthermore, the reporter oligonucleotide can form stem-
60 loop hairpin structure to minimize its interactions with 
strands a and ~ in the absence of the analyte. This assay is 
adoptable to microarray format as described below. 
Restriction endonuclease-based binary probe assay: This 
embodiment takes advantage of recognition and cleavage of 
specific DNA sequences by restriction endonucleases. The 
restriction site-forming sequences are included in the reporter 
oligonucleotide and in the oligonucleotide-binding arm of 
strands a, ~'or both a and~· As shown in FIG. 3, more than 
one such sequence can be included in the reporter oligonucle- 65 
otide. Since restriction endonucleases do not recognize single 
stranded nucleic acid regions that would be present in the 
Example 9 
Microarrays of enzyme assisted binary probes: The sys-
tems of the disclosure can be adapted to the solid-support 
US 8,859,266 B2 
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based formats such as microarrays. In microarrays, one of the 
oligonucleotide probes can be attached to the surface of a 
solid support, while a second strand and the analyte will be 
added in solution, hybridized with the solid-support bound 
strand, followed by treatment with a specific DNA processing 
enzyme. 
For example, as schematically shown in FIG. 10, a DNA 
glycosylase-based assay according to Example 8 can be con-
verted to the microarray format. FIG. 10 shows microarray 
features, each of which contains covalently attached one 
strand of the binary probe (strand a in FIG. 10). The analyte 
and strand~ are incubated with the microarray in the presence 
of the reporter oligonucleotide. The reporter oligonucleotide 
contains damages or mismatch-forming nucleotide(s) conju-
gated with the quencher dye. When the quadripartite complex 
is formed, the specific DNA glycosylase can be added to the 
microarray and cleaves off the quencher conjugated bases. 
The remaining quadripartite complex emits bright fluores-
cence, which can be detected by a conventional fluorescent 
scanner. 
<160> NUMBER OF SEQ ID NOS, 12 
<210> SEQ ID NO 1 
<211> LENGTH, 28 
<212> TYPE, DNA 
SEQUENCE LISTING 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, HepC30 fragment analyte 
<400> SEQUENCE, 1 
tgccccggag gtctgtagac cgtgcacc 
<210> SEQ ID NO 2 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Enz-BDPl strand alpha 
<400> SEQUENCE, 2 
gaccatctca gacctcccgg g 
<210> SEQ ID NO 3 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Enz-BDPl strand beta 
<400> SEQUENCE, 3 
cacggtctac gttcctatag 
<210> SEQ ID NO 4 
<211> LENGTH, 28 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
24 
Example 10 
Deoxyribozyme assisted probe system: This type of probe 
is related to enzyme-assisted probes, although the protein 
enzyme is not required. The absence of a protein enzyme 
reduces cost of the assay, and makes the assay system more 
stable with a longer shelf-life. 
In this embodiment of the probe system, at least one of the 
oligonucleotide probes binding to the target analyte contains 
10 a deoxyribozyme sequence embedded in the oligonucleotide 
molecular beacon-binding arm. 
Presence of the specific nucleic acid analyte results in the 
formation of a quadripartite complex (FIG. 11) in which the 
deoxyribozyme binds opposite the cleavable site (X) in the 
15 reporter oligonucleotide. The cleavage of the reporter oligo-
nucleotide leads to separation of fluorophore and the 
quencher, thus generating high fluorescent signal. In the 
example illustrated in FIG. 13, the two oligonucleotides of the 
binary probe independently encode different deoxyri-
bozymes. 
28 
21 
20 
<223> OTHER INFORMATION, Molecular Beacon 1 (MBl) conjugated to 
fluorescein and Black Hole Quencher 1 and N is ribonucleotide A 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (13) .. (13) 
<223> OTHER INFORMATION, n is ribonucleotide a 
US 8,859,266 B2 
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<400> SEQUENCE, 4 
ccgactcact atnggaagag atggtcgg 
<210> SEQ ID NO 5 
<211> LENGTH, 40 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
-continued 
<223> OTHER INFORMATION, HepC40 fragment analyte 
<400> SEQUENCE, 5 
ttcatcgtct cgccgcagta ccactggttt gtgcaagaat 
<210> SEQ ID NO 6 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Enz-BDP2 strand alpha 
<400> SEQUENCE, 
gatctattgg tactgcggcg a 
<210> SEQ ID NO 7 
<211> LENGTH, 22 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Enz-BDP2 strand beta 
<400> SEQUENCE, 7 
gcacaaacca gtgtatgtta ac 
<210> SEQ ID NO 8 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Molecular beacon 2 (MB2) conjugated to 
fluorescein and BHQ-1 (Nis ribonucleotide A) 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (8) .. (8) 
<223> OTHER INFORMATION, n is ribonucleotide a 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (17) .. (17) 
<223> OTHER INFORMATION, n is ribonucleotide a 
<400> SEQUENCE, 8 
cgcgttanca tacaatngat cgcg 
<210> SEQ ID NO 9 
<211> LENGTH, 42 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, HepC fragment analyte 
<400> SEQUENCE, 9 
cttttctatc ttcttgctgg ccctgttgtc ctgcatcacc gt 
<210> SEQ ID NO 10 
<211> LENGTH, 48 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
26 
28 
40 
21 
22 
24 
42 
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-continued 
<220> FEATURE, 
<223> OTHER INFORMATION, strand alpha 
<400> SEQUENCE, 10 
gaccaggcta gctcaacgat ctcttcggcc agcaagaaga tagaaaag 
<210> SEQ ID NO 11 
<211> LENGTH, 44 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, strand beta 
<400> SEQUENCE, 11 
acggtgatgc aggacaacag agggaggcta gctcaacgag agga 
<210> SEQ ID NO 12 
<211> LENGTH, 32 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
48 
44 
<223> OTHER INFORMATION, Molecular Beacon conjugated to FAM and BHQl 
(where in cnnc, nn are ribonucleotides gu, and in gnng, nn are 
ribonucleotides au) 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (10) .. (11) 
<223> OTHER INFORMATION, nn is ribonucleotide pair gu; 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (24) .. (25) 
<223> OTHER INFORMATION, nn is ribonucleotide pair au; 
<400> SEQUENCE, 12 
cgcgtcctcn nccctgaaga gagnnggtcg cg 
We claim: 
1. A system for detecting a target analyte, the system com-
32 
label and the quencher, wherein the cleavable site is 
characterized as cleavable by a protein enzyme; and 
~~: ~ 
(a) a first oligonucleotide probe comprising: (i) at the 5'-ter-
wherein the target analyte, the first and second oligonucle-
otide probes, and the reporter oligonucleotide form a 
quadripartite complex, thereby providing a configura-
tion of the cleavable site of the reporter oligonucleotide 
allowing said site to be cleaved by the protein enzyme. 
minus thereof, a reporter oligonucleotide-binding arm 
having a nucleotide sequence complementary to the 
nucleotide sequence of a first region of a reporter oligo-
nucleotide; and (ii) at the 3'-terminus thereof, an ana-
lyte-binding arm having a nucleotide sequence charac-
terized as selectively binding to a first region of a target 
analyte; 
(b) a second oligonucleotide probe comprising: (i) at the 
3'-terminus thereof, a reporter oligonucleotide-binding 
arm having a nucleotide sequence complementary to the 
nucleotide sequence of a second region of a reporter 
oligonucleotide; and (ii) at the 5'-terminus thereof, an 
analyte-binding arm having a nucleotide sequence char-
acterized as selectively binding to a second region of a 
target analyte; 
2. The system of claim 1, wherein a cleavable site of the 
45 reporter oligonucleotide comprises a ribonucleotide. 
3. The system of claim 1, wherein the reporter oligonucle-
otide-binding arm of at least one oligonucleotide probe com-
prises a nucleotide sequence that provides a site in the 
reporter oligonucleotide specifically cleavable by a restric-
50 ti on endonuclease when said oligonucleotide probe is hybrid-
ized to the reporter oligonucleotide, and the oligonucleotide-
cleaving agent is said restriction endonuclease. 
4. The system of claim 1, wherein the protein enzyme is 
selected from the group consisting of: a restriction endonu-
55 clease, an RNase H, a Flap-endonuclease-1 (FEN-1), and a 
DNA glycosylase. 
5. The system of claim 1, wherein at least one of the first 
oligonucleotide probe and the second oligonucleotide probe 
further comprises a linker connecting the analyte-binding 
60 arm and the reporter oligonucleotide-binding arm of said 
oligonucleotide probe. 
( c) a reporter oligonucleotide comprising: (i) a first region 
having a nucleotide sequence complementary to the 
reporter oligonucleotide-binding arm of the first oligo-
nucleotide probe; (ii) a second region having a nucle-
otide sequence complementary to the reporter oligo-
nucleotide-binding arm of the second oligonucleotide 
pro be; (iii) a fluorophore and a quencher disposed on the 
reporter oligonucleotide whereby said fluorophore and 
quencher interact in the absence of a target analyte to 65 
quench fluorescence generated by the fluorophore; and 
(iv) a cleavable site disposed between the fluorescent 
6. The system of claim 1, wherein the reporter oligonucle-
otide is a molecular beacon characterized as having a stem-
loop configuration in the absence of a target analyte. 
7. The system of claim 1, wherein at least one of the 
fluorophore and the quencher is attached to the reporter oli-
gonucleotide at the 5' or the 3' terminus thereof. 
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8. The system of claim 1, wherein the nucleotide sequences 
of the analyte-binding arms of the first and the second oligo-
nucleotide probes are independently selected to specifically 
bind to a target analyte comprising a deoxyribonucleotide 
sequence, a ribonucleotide sequence, a double-stranded 
nucleic acid, a peptide, a polypeptide, or a variant thereof. 
9. The system of claim 1, wherein the first or the second 
oligonucleotide probe is tethered to a substrate. 
10. The system of claim 1, further comprising a plurality of 
oligonucleotide probe pairs, each probe pair comprising a 10 
first oligonucleotide probe and a second oligonucleotide 
probe. 
11. The system of claim 10, wherein one oligonucleotide 
probe in each probe pair is tethered to a substrate. 
12. The system of claim 11, wherein the oligonucleotide 15 
probe in each probe pair of the plurality of oligonucleotide 
probes is disposed on the substrate as an array. 
13. A method of identifying a target analyte in a test 
sample, the method comprising the steps of: 
(i) forming a reaction mix by combining the test sample 20 
with: 
(a) a first oligonucleotide probe comprising: (i) at the 
5'-terminus thereof, a reporter oligonucleotide-bind-
ing arm having a nucleotide sequence complementary 
to the nucleotide sequence of a first region of a 25 
reporter oligonucleotide; and (ii) at the 3'-terminus 
thereof, an analyte-binding arm having a nucleotide 
sequence characterized as selectively binding to a first 
region of a target analyte; 
(b) a second oligonucleotide probe comprising: (i) at the 30 
3'-terminus thereof, a reporter oligonucleotide-bind-
ing arm having a nucleotide sequence complementary 
to the nucleotide sequence of a second region of a 
reporter oligonucleotide; and (ii) at the 5'-terminus 
thereof, an analyte-binding arm having a nucleotide 35 
sequence characterized as selectively binding to a 
second region of a target analyte; 
( c) a reporter oligonucleotide comprising: (i) a first 
region having a nucleotide sequence complementary 
to the reporter oligonucleotide-binding arm of the first 40 
oligonucleotide probe; (ii) a second region having a 
nucleotide sequence complementary to the reporter 
oligonucleotide-binding arm of the second oligo-
nucleotide probe; (iii) a fluorophore and a quencher 
disposed on the reporter oligonucleotide whereby 45 
said fluorophore and quencher interact in the absence 
of a target analyte to quench fluorescence generated 
by the fluorophore; and (iv) a cleavable site disposed 
between the fluorescent label and the quencher, 
wherein the cleavable site is characterized as cleav- 50 
able by a protein enzyme or a region of the first, and 
30 
the fluorophore, the quencher, or both the fluorophore 
and the quencher, from the quadripartite complex; 
(iv) illuminating the reaction mix at a wavelength suitable 
for inducing a fluorescent emission by the fluorophore; 
and 
(v) detecting the fluorescence emitted by the fluorophore, 
thereby detecting the presence of the target analyte in the 
test sample. 
14. A kit comprising: 
(a) a first oligonucleotide probe comprising: (i) at the 5'-ter-
minus thereof, a reporter oligonucleotide-binding arm 
having a nucleotide sequence complementary to the 
nucleotide sequence of a first region of a reporter oligo-
nucleotide; and (ii) at the 3'-terminus thereof, an ana-
lyte-binding arm having a nucleotide sequence charac-
terized as selectively binding to a first region of a target 
analyte; 
(b) a second oligonucleotide probe comprising: (i) at the 
3'-terminus thereof, a reporter oligonucleotide-binding 
arm having a nucleotide sequence complementary to the 
nucleotide sequence of a second region of a reporter 
oligonucleotide; and (ii) at the 5'-terminus thereof, an 
analyte-binding arm having a nucleotide sequence char-
acterized as selectively binding to a second region of a 
target analyte; 
( c) a reporter oligonucleotide comprising: (i) a first region 
having a nucleotide sequence complementary to the 
reporter oligonucleotide-binding arm of the first oligo-
nucleotide probe; (ii) a second region having a nucle-
otide sequence complementary to the reporter oligo-
nucleotide-binding arm of the second oligonucleotide 
probe; (iii) a fluorophore and a quencher disposed on the 
reporter oligonucleotide whereby said fluorophore and 
quencher interact in the absence of a target analyte to 
quench fluorescence generated by the fluorophore; and 
(iv) a cleavable site disposed between the fluorescent 
label and the quencher, wherein the cleavable site is 
characterized as cleavable by a protein enzyme, and 
wherein one oligonucleotide probe in each probe pair 
optionally is tethered to a substrate, and optionally dis-
posed on the substrate as an array; wherein the target 
analyte, the first and second oligonucleotide probes, and 
the reporter oligonucleotide form a quadripartite com-
plex, thereby providing a configuration of the cleavable 
site of the reporter oligonucleotide allowing said site to 
be cleaved by the protein enzyme; and 
( d) optionally, packaging and instructions for the use of the 
kit to detect a target analyte in a test sample. 
15. The kit of claim 14, further comprising a plurality of 
oligonucleotide probe pairs, each probe pair comprising a 
first oligonucleotide probe and a second oligonucleotide 
probe. 
(ii) incubating the reaction mix under conditions suitable 
for the formation of a quadripartite complex between the 
analyte-binding arms of the first and the second oligo-
nucleotide probes, the target analyte in the test sample, 
and the reporter oligonucleotide, thereby exposing a 
cleavable site of the reporter oligonucleotide for cleav-
age; 
55 16. The kit of claim 15, wherein one oligonucleotide probe 
in each probe pair is tethered to a substrate. 
(iii) cleaving at the cleavable site of the reporter oligo-
nucleotide with the protein enzyme, thereby releasing 
17. The kit of claim 16, wherein the oligonucleotide probe 
in each probe pair of the plurality of oligonucleotide probes is 
disposed on the substrate as an array. 
* * * * * 
